|
MaxCyte Inc on Monday said it signed a strategic platform licence with Vittoria Biotherapeutics to advance cellular therapies. The cell-engineering technology platform based in Maryland, US said under the terms of the agreement, Vittoria will obtain non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation technology and ExPERT platform. Meanwhile, MaxCyte will have access to platform licensing fees and program-related revenue. Vittoria Therapeutics is a gene-edited therapeutics company specialising in platform technologies for cellular therapies. MaxCyte Chief Executive Officer Doug Doerfler said: ‘Through our partnership with Vittoria, MaxCyte has gained an opportunity to further validate and showcase our technology in a real-world setting and expand its footprint in the promising field of CAR-T therapies. We look forward to supporting Vittoria’s efforts to improve efficacy and enhance safety of T-cell therapies.’ Shares in MaxCyte were up 0.9% at 353.00 pence each in London on Monday afternoon. Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
